288 related articles for article (PubMed ID: 26847553)
1. Association between glaucoma eye drops and hyperemia.
Yanagi M; Kiuchi Y; Yuasa Y; Yoneda T; Sumi T; Hoshikawa Y; Kobayashi M; Fukushima A
Jpn J Ophthalmol; 2016 Mar; 60(2):72-7. PubMed ID: 26847553
[TBL] [Abstract][Full Text] [Related]
2. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
[TBL] [Abstract][Full Text] [Related]
4. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
[TBL] [Abstract][Full Text] [Related]
5. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
7. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
8. Time Course of Prostaglandin Analog-related Conjunctival Hyperemia and the Effect of a Nonsteroidal Anti-inflammatory Ophthalmic Solution.
Sakata R; Sakisaka T; Matsuo H; Miyata K; Aihara M
J Glaucoma; 2016 Mar; 25(3):e204-8. PubMed ID: 25642812
[TBL] [Abstract][Full Text] [Related]
9. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.
Sakamoto E; Ishida W; Sumi T; Kishimoto T; Tada K; Fukuda K; Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
Sci Rep; 2019 Mar; 9(1):3755. PubMed ID: 30842572
[TBL] [Abstract][Full Text] [Related]
14. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
[TBL] [Abstract][Full Text] [Related]
15. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
Kobayashi H; Kobayashi K
J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
[TBL] [Abstract][Full Text] [Related]
16. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic.
McKinley SH; Singh R; Chang PT; Gross RL; Orengo-Nania S
J Ocul Pharmacol Ther; 2009 Apr; 25(2):153-7. PubMed ID: 19284329
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension.
Feldman RM
J Ocul Pharmacol Ther; 2003 Feb; 19(1):23-35. PubMed ID: 12648301
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
[TBL] [Abstract][Full Text] [Related]
20. Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications.
Di Zazzo A; Roberti G; Mashaghi A; Abud TB; Pavese D; Bonini S
J Ocul Pharmacol Ther; 2017 Nov; 33(9):670-677. PubMed ID: 29045169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
